| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $11.56B | +30.1% |
| Cost of Revenue | $6.00B | +36.1% |
| Gross Profit | $5.55B | +24.2% |
| R&D Expense | $1.54B | +12.4% |
| SG&A Expense | $471.0M | +14.9% |
| Operating Income | $1.47B | +36.6% |
| Pre-tax Income | $1.51B | -32.3% |
| Income Tax | $278.0M | +33.0% |
| Net Income | $1.23B |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.54B | +3.1% |
| Short-term Investments | $4.23B | +6.3% |
| Accounts Receivable | $500.0M | +46.2% |
| Inventory | $21.0M | -19.2% |
| Current Assets | $8.30B | +14.4% |
| Total Assets | $15.19B | +9.1% |
| Current Liabilities | $1.39B | -28.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $2.03B | +25.8% |
| Capital Expenditures | $26.0M | +36.8% |
| Investing Cash Flow | -$1.19B | +25.0% |
| Financing Cash Flow | -$811.0M | -1429.5% |
| Free Cash Flow | $2.01B | +25.7% |
| -39.0% |
| EPS (Basic) | $0.95 | -39.5% |
| EPS (Diluted) | $0.94 | -39.4% |
| Stockholders' Equity |
| $13.47B |
| +16.6% |